Company intelligence / Profile preview

Argos

Durham, North Carolina, United Statesargos.co.uk ↗

Ownership: Private
Development stage: Other

Overview

Lead candidate rocapuldencel-T (AGS-003) for metastatic renal cell carcinoma reached Phase 3 but was discontinued after failing to meet primary endpoints. AGS-004, a dendritic cell immunotherapy for HIV infection, reached Phase 2. CD83 soluble protein for transplant rejection and anti-IFNα monoclonal antibody for lupus were in preclinical or early clinical stages.

Therapeutic areas: Infectious DiseasesOncologyImmunology
Modalities: Dendritic cell therapyMonoclonal antibodyTherapeutic vaccineProtein
Industry: Biotech

Partnerships

Duke University

Beyond the preview

Go deeper on Argos.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Argos.

Explore the full profile